Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

IMV Inc IMVIF

Healthcare Biotechnology
IMV Inc. is a Canada-based company. The Company has no business operations.


GREY:IMVIF - Post by User

IMV Inc
Bullboard Posts
User Avatar Image
(0)
•••
Post by PoorOpinionon Jun 25, 2018 8:35pm
149 Views
Post# 28227284

Ors video interview at ASCO

Ors video interview at ASCONot sure if this video made it to the board. Again underlines the MOA is what is most exciting management. Honestly I think this changes the nature of the conversation they have with partners etc when you can show proof of T-cell infiltration. (Sorry to bang on about this)

https://www.healio.com/hematology-oncology/gynecologic-cancer/news/online/%7Bb70174d7-7e34-4fbc-add4-b4f2fd08a87f%7D/video-immunotherapy-combination-demonstrates-efficacy-in-advanced-ovarian-cancer



Bullboard Posts
Dealroom for high-potential pre-IPO opportunities